Market Update: Eli Lilly & Company (NYSE:LLY) – Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

[PR Newswire] – RIDGEFIELD, Conn., and INDIANAPOLIS, Sept. 17, 2015 /PRNewswire/ — Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company’s (LLY) Jardiance® (empagliflozin) significantly reduced the risk of the combined endpoint . . . → Read More: Market Update: Eli Lilly & Company (NYSE:LLY) – Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial Similar Articles: Company Update (NYSE:LLY): Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events Market Update: Eli Lilly & Company (NYSE:LLY) – FDA asks panel to weigh benefit, risk of Lilly lung cancer drug Market Update (NYSE:LLY): Studies Show Psoriasis Patients Achieved Significant Levels of Skin Clearance and Improved Quality of Life after 12 Weeks of Ixekizumab Treatment